DEENOVA
3.5.2022 07:02:13 CEST | Business Wire | Press release
Today, Deenova announced that it is launching its innovative Pay-Per-Dose unit dose pharmacy automation service to the UK market for the first time. Deenova was the first company to bring a fully automated, closed-loop solution for the management of medication and medical supplies to the UK following a hugely successful pilot at University Hospitals Leicester . This newly designed Pay-Per-Dose solution is initially offered in late 2022 for the Greater London Metropolitan Area to both NHS and private hospitals. Deenova thus opens its market reach to short-term and easy-to-adopt contractual arrangements and flexibility in England´s Pharmacy Automation market.
Deenova is making the unit dose concept a reality in the UK. Its end-to-end pharmacy automation service not only personalises medicine dispensation and administration to individual patients, but enables closed-loop medication management; fully tracking and managing medicines from prescription, through to patient administration. This innovative approach promises to ease growing pressures on healthcare providers in the UK by increasing patient safety, reducing treatment dispensing errors and medicine waste, containing costs, and saving nurses’ and pharmacists’ time. This approach promises to ease growing pressures on healthcare providers in the UK by increasing patient safety, reducing treatment dispensing errors and medicine waste, containing costs, and saving nurses’ and pharmacists’ time.
Gaspar G. De Viedma , Vice Chairman of the Board of Directors at Deenova stated: “I am very bullish about this exciting new venture, especially on the heels of our 15-year award from University Hospitals of Leicester NHS Trust in Europe´s second largest GDP healthcare market, and after the first ever successful unit dose implementation in the United Kingdom. The patient safety and economic advantages of Deenova ´s unique closed-loop medication unit dose system were already clearly evidenced by the positive evaluation report issued by the East Midlands Academic Health Science Network (AHSN) following an 18-month evaluation of Deenova ’s closed-loop solutions.”
The new pay-per-dose unit dose pharmacy automation is a full service, yet modular solution. It includes Deenova’s ORBIT Software for e-prescribing and micro-logistic management, all IT infrastructure hosting and integration with hospital Health Information Systems (HIS), its proprietary and award winning mechatronic devices for the production of unit doses , and the All-In-1 Station - a fully automated solution for the dispensation of personalised therapies. Deenova ’s pay-per-dose service also includes staff to manage the full medication traceability process, as well all support functions such as training, maintenance, hot line support, analytics and reporting.
Deenova will officially launch its pay-per-dose unit dose pharmacy automation solution during the UK Clinical Pharmacy Congress at the lunch time symposia show, floor theatre, Friday 13 May at 1:00pm.
Christophe Jaffuel , Deenova´s Chief Commercial Officer, added: “Deenova has been delivering end-to-end unit dose solutions across Europe for decades. I look forward to personally working with English hospitals in the Greater London Metropolitan Area, and with our newly appointed UK Commercial Director Andrew Lyon in making these extremely flexible and cost effective solutions a successful reality for Deenova .”
About Deenova
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Deenova have been delivering unit dose solutions provided as a complete end-to-end service to hospitals across Europe for 18 years, with more than 70 projects to date - partnering with regional healthcare trusts to deliver results at scale.
Please visit www.deenova.com for additional information on its market-leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005779/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom